Is There a Role for α-Blockers in Ureteral Stent Related Symptoms? A Systematic Review and Meta-Analysis
- 1 September 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 186 (3) , 928-934
Abstract
Purpose: We evaluated the efficacy of alpha-blockers to improve ureteral stent related morbidity and quality of life. Materials and Methods: We performed a search of MEDLINE (R), Embase (TM) and The Cochrane Library plus a hand search of conference proceedings from January 2000 to October 2010 to identify randomized, controlled trials comparing treatment for ureteral stent symptoms with alpha-blockers. Two reviewers independently screened studies and extracted data. Trial methodological quality was assessed by The Cochrane Collaboration quality assessment tool. Placebo randomized, controlled trials with the ureteral stent symptom questionnaire as the outcome were eligible for meta-analysis. Meta-analysis was done using the mean difference to determine the aggregate effect size. Results: A total of 12 randomized, controlled trials including 2 alpha-blockers in a total of 946 patients were eligible, including 4 (33%) presented only as an abstract at a urological meeting and 4 (33%) eligible for meta-analysis. Meta-analysis using a random effects model showed that alpha-blockers were associated with a significant decrease in urinary symptoms (MD -6.76, 95% CI -11.52 to -2.00, p = 0.005), a significant decrease in pain (MD -3.55, 95% CI -5.51 to -1.60, p = 0.0004) and significant improvement in general health (MD -1.90, 95% CI -3.05 to -0.75, p = 0.001). However, they were not associated with a benefit in work (MD 2.41, 95% CI -1.62 to 6.44, p = 0.24) or sexual matters (MD 0.20, 95% CI -1.06 to 1.45, p = 0.33). Eight studies were not included in the meta-analysis, of which 7 showed a significant clinical decrease in urinary symptoms and pain. Conclusions: Existing evidence from randomized, controlled trials shows that alpha-blockers are associated with improvement in ureteral stent symptoms and supports their use in routine clinical practice.Keywords
This publication has 27 references indexed in Scilit:
- Efficacy of Tamsulosin 0.4 mg/day in Relieving Double-J Stent-Related Symptoms: A Randomized Controlled StudyJournal of International Medical Research, 2010
- Prospective Randomized Evaluation of Periureteral Botulinum Toxin Type A Injection for Ureteral Stent Pain ReductionJournal of Urology, 2010
- Stent Position Is More Important than α-Blockers or Anticholinergics for Stent-Related Lower Urinary Tract Symptoms after Ureteroscopic Ureterolithotomy: A Prospective Randomized StudyKorean Journal of Urology, 2010
- Alfuzosin to Relieve Ureteral Stent Discomfort: A Prospective, Randomized, Placebo Controlled StudyJournal of Urology, 2009
- Ureteral stent discomfort: Etiology and managementIndian Journal of Urology, 2009
- EFFECTS OF TAMSULOSIN AND TOLTERODINE ON LOWER URINARY TRACT SYMPTOMS DEVELOPED FROM URETERAL STENT: PROSPECTIVE MULTICENTER STUDYJournal of Urology, 2008
- A systematic review identifies a lack of standardization in methods for handling missing variance dataJournal of Clinical Epidemiology, 2006
- Second Prize: Double-Blind Randomized Controlled Trial Assessing the Safety and Efficacy of Intravesical Agents for Ureteral Stent Symptoms after Extracorporeal Shockwave LithotripsyJournal of Endourology, 2004
- Ureteral Stent Symptom Questionnaire: Development and Validation of a Multidimensional Quality of Life MeasureJournal of Urology, 2003
- Indwelling Ureteral Stents: Evaluation of Symptoms, Quality of Life and UtilityJournal of Urology, 2003